An Outpatient Study of the Efficacy of ARS-2 in Patients With Chronic Spontaneous Urticaria

NCT ID: NCT06927999

Last Updated: 2025-10-02

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE2
• Total Enrollment: 42 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-07-09
• Study Completion Date: 2026-06-30

Brief Summary

This is a Phase 2b, outpatient, single-dose, randomized, double blind, placebo-controlled, three period crossover study that will consist of a screening period and three blinded treatment periods. Subjects enrolled will have CSU with a history of moderate to severe acute exacerbations (or flares).

Conditions

Urticaria Chronic

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

Placebo

Placebo solution nasal spray containing no active drug will be administered using the commercial sprayer device.

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Placebo solution nasal spray containing no active drug

0.5 mg

0.5 mg epinephrine per spray

Group Type: ACTIVE_COMPARATOR

0.5 mg epinephrine

Intervention Type: DRUG

0.5 mg epinephrine per spray

1 mg

1 mg epinephrine per spray

Group Type: ACTIVE_COMPARATOR

1 mg epinephrine

Intervention Type: DRUG

1 mg epinephrine per spray

Interventions

Placebo

Placebo solution nasal spray containing no active drug

Intervention Type: DRUG

0.5 mg epinephrine

0.5 mg epinephrine per spray

Intervention Type: DRUG

1 mg epinephrine

1 mg epinephrine per spray

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Is a male or female between the ages of 18 and 65 years, inclusive.
• Has been clinically diagnosed with CSU and experiences an acute flare of moderate to severe urticaria symptoms (itch and hive severity UAS score ≥ 2) approximately 1-2 times a month or every other month consistently during the past year while on a chronic treatment.
• Has been on a daily chronic treatment for ≥ 6 weeks.
• Is willing to use a smartphone study application to record study assessments and AEs.
• Has body weight more than 15 kilogram (kg).
• Has no medical history of clinically significant hypertension and cardiovascular disease in the last 10 years
• If female, is not pregnant or breastfeeding based on a negative urine pregnancy test at baseline.
• Is able to communicate clearly with the Investigator and staff; able to read, complete questionnaires, and perform study procedures on the smartphone study application.
• Is willing and able to provide written informed consent prior to participating in the study.
• Controlled hypertension without beta blocker confirmed by the Investigator is acceptable.
• At screening, has stable vital signs in the following ranges (after 5 minutes of rest):

• Systolic blood pressure (SBP) ≥90 and ≤140 milliliters of mercury (mmHg)
• Diastolic blood pressure (DBP) ≥50 and ≤90 mmHg
• Heart rate (HR) ≥45 and ≤100 beats per minute (bpm)

Exclusion Criteria

• Has a history of clinically significant gastrointestinal, renal, hepatic, neurologic, hematologic, endocrine, oncologic, pulmonary, immunologic, psychiatric, or cardiovascular disease or any other condition which, in the opinion of the Investigator, would jeopardize the safety of the subject or impact the validity of the study results.
• Has any clinically significant medical condition or PE finding as deemed inappropriate by the Investigator.
• Has abnormal cardiovascular exam at screening including any prior history of myocardial infarction or clinically significant abnormal electrocardiogram (ECG)
• Has had significant traumatic injury or major surgery within 30 days prior to study screening.
• Known hypersensitivity to any compound in the test product, or any other closely related compound (e.g., dihydropyridine-derived molecules).
• Has participated in a clinical trial within 30 days prior to the first dose of study drug.
• Has an immediate family member of the Investigator, or an employee of the study center, with direct involvement in the proposed study, or other studies under the direction of the Investigator or study center or is in a dependent relationship with a study center employee who is involved in the conduct of this study (e.g., spouse, parent, child, sibling), or may consent under duress.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

ARS Pharmaceuticals, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Endeavor Health Clinical Trials Center

Glenview, Illinois, United States

Site Status: RECRUITING

Bernstein Clinical Research Center, LLC

Cincinnati, Ohio, United States

Site Status: RECRUITING

Institute of Allergology IFA Charité - Campus Benjamin Franklin | Hindenburgdamm 30

Berlin, , Germany

Site Status: NOT_YET_RECRUITING

Countries

United States; Germany

Central Contacts

Osnat Ehrman, MSc

Role: CONTACT

osnate@pacificlinkconsulting.com

952.334.5797

Facility Contacts

Giselle Mosnaim, MD

Role: primary

Gmosnaim@northshore.org

847-998-4170

Other Identifiers

EPI U02

Identifier Type: -

Identifier Source: org_study_id